Check Cap Ltd (MBAI) Stock Analysis

AI analysis of Check Cap Ltd (MBAI)

Hold

Currently, Check Cap Ltd (MBAI) is not a strong buy due to its low current price of $1.78, which is significantly below its 52-week high of $27.44, indicating a major decline of 85.17% year-to-date. The RSI is at 26.029, suggesting that the stock is oversold, but this could also indicate continued weakness. The forward P/E ratio is 1.2655, which is attractive, but the company is still facing significant financial challenges, including a negative EPS of -30.10 for Q4 2024 and a current ratio of only 0.15, indicating liquidity issues. The main risk is the ongoing volatility, as evidenced by a 5-day change of -8.72%.

Valuation Metrics

The current forward P/E ratio for Check Cap Ltd (MBAI) is 1.27, compared to its 5-year average forward P/E of 0.91.

Forward P/E

Fair

5Y Average P/E

0.91

Current P/E

1.27

Overvalued

1.48

Undervalued

0.33

Forward EV/EBITDA

Overvalued

5Y Average EV/EBITDA

4.15

Current EV/EBITDA

11.05

Overvalued

10.08

Undervalued

-1.78

Forward P/S

Overvalued

5Y Average P/S

0.90

Current P/S

2.36

Overvalued

2.16

Undervalued

-0.35

MBAI FAQ — answered by Alphio AI

MBody AI Ltd., formerly Check-Cap Ltd, is an Israel-based artificial intelligence (AI) software company focused on embodied AI and robotics management solutions. The Company develops the MBody AI Orchestrator, a software platform designed to coordinate, monitor, and optimize fleets of autonomous robots across enterprise environments. Its platform provides multi-vendor robot control, AI-driven performance optimization, task verification, reporting, and operational analytics capabilities. The Company also provides software, implementation, training, maintenance, and support services related to robotic deployments. MBody AI serves customers in hospitality and other labor-intensive industries through AI-enabled automation and fleet management solutions. It operates in the Healthcare sector.

Currently, Check Cap Ltd (MBAI) is not a strong buy due to its low current price of $1.78, which is significantly below its 52-week high of $27.44, indicating a major decline of 85.17% year-to-date. The RSI is at 26.029, suggesting that the stock is oversold, but this could also indicate continued weakness. The forward P/E ratio is 1.2655, which is attractive, but the company is still facing significant financial challenges, including a negative EPS of -30.10 for Q4 2024 and a current ratio of only 0.15, indicating liquidity issues. The main risk is the ongoing volatility, as evidenced by a 5-day change of -8.72%.